4 research outputs found
Additional file 1: of Post-mortem histopathology underlying ÃŽË›-amyloid PET imaging following flutemetamol F 18 injection
Example of the recording of pathology sampling to enable mapped cortical tracer retention SUVRs to be measured for correlation. Regions sampled from the lateral surface include the Midfrontal lobe (MFL), Superior Temporal Gyrus (STG), Middle Temporal Gyrus (MTG) and Inferior Parietal Lobe. Regions sampled from the medial surface include Anterior Cingulate Gyrus (ACG), Posterior Cingulate Gyrus (PCG), Precuneus (PRC) and Primary Visual Cortex (PVC). (DOC 90 kb
Additional file 5: of Post-mortem histopathology underlying ÃŽË›-amyloid PET imaging following flutemetamol F 18 injection
Clinical Status of subjects at PET Scan. Spontaneously recorded clinical notes captured at the time of PET scan. The PET category provided reflects PET majority image assessment against pathology dichotomy normal/abnormal by mCERADSOT. (DOC 155 kb
Additional file 2: of Post-mortem histopathology underlying ÃŽË›-amyloid PET imaging following flutemetamol F 18 injection
Receiver operator characteristic (ROC) analysis of regional histometric measures and standard retention value ratios. Regional analysis of 32 brains provided retention correlation with plaque burden and provided a large data set (N = 256) with which to estimate the lower limit of detection. For regional analysis SUVR baselines which varied between regions due to variable adjacent white-matter signal bleed were used to define a threshold for each region. Thresholds were determined post-hoc by ROC analysis as the maximal sum of the sensitivity (true positive rate) and specificity (1 - false-positive rate). (DOC 59 kb
Additional file 4: of Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
ROC Analysis: Dichotomised pathology vs continuous SUVR. Comparison of 5 histopathological criteria of assigning abnormal amyloid against PET signal quantification (SUVR). Histopathological criteria used were: CERAD [43] moderate or frequent = abnormal; National Institutes of Ageing – Reagan Institute [26] Intermediate or High = abnormal; National Institutes of Ageing – Alzheimer’s Association [25] Intermediate or High = abnormal; Thal 3+ Thal amyloid phase [58] of 3 or higher = abnormal; Thal 4+ Thal amyloid phase [58] of 4 or 5 = abnormal. (DOC 241 kb